Download PDFPDF

814 Cutaneous immune-related adverse events are protective of mortality in patients treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address